FLAG-IDA-Venetoclax for high-risk newly diagnosed acute myeloid leukemia: a multicenter real-world study

Key Points

• This research aims to evaluate the effectiveness of FLAG-IDA combined with venetoclax in treating high-risk acute myeloid leukemia.
• Multicenter real-world study design
• Focus on high-risk newly diagnosed acute myeloid leukemia patients
• Administered FLAG-IDA with venetoclax as treatment
• Analyzed treatment outcomes and patient responses
• Improved response rates observed in high-risk acute myeloid leukemia patients
• Increased survival rates compared to historical controls
• Notable reduction in treatment-related side effects